Sun Pharmaceutical Industries Limited (SUNPHARMA)
Investor Presentation
Investor Presentation - Sept 2026
- FY26 sales Rs 582 Bn, +12% y-y; EBITDA Rs 177.3 Bn, 30.3% margin
- US business: 13th largest generics, 29% revenue share, strong pipeline
- India business: largest pharma company with 8.5% market share, 33% revenue share
- Emerging Markets and Rest of World growing with 19% and 15% revenue share
- R&D spend 6.1% of sales; 40 manufacturing facilities globally
- Q1 FY27 sales Rs 153 Bn, +10.5% y-y; EBITDA margin 28.9%; net profit Rs 29 Bn, +27% y-y
- Focus on innovative medicines, complex generics, sustainability, and profitable growth
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SUNPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SUNPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Sun Pharmaceutical Industries Limited
Important.
The summary above is generated automatically from Sun Pharmaceutical Industries Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.